DarioHealth Corp. (DRIO) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, filed on August 15, 2022, serves as a current report announcing the release of financial results for the three and six months ended June 30, 2022. The Company, an emerging growth company incorporated in Delaware, operates on The Nasdaq Capital Market. The filing references a press release and a presentation (Exhibits 99.1 and 99.2) containing the detailed financial data.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced Exhibits 99.1 and 99.2, which are not included in the provided text. The Company utilizes non-GAAP financial measures to evaluate operational performance, specifically adjusting operating expenses and operating loss to exclude inventory step-up amortization, amortization of acquired technology, stock-based compensation, depreciation, amortization of acquired brand, and earn-out revaluation.
Material Changes and Comparisons
The filing text does not disclose specific material changes or comparative data versus prior periods. Investors must refer to the attached presentation and press release for year-over-year or quarter-over-quarter analysis.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future outlook, or a detailed discussion of risks and contingencies within the main body text. The Company notes that non-GAAP measures are not standardized under GAAP and may not be comparable to peer companies. Investors are explicitly encouraged to review the reconciliation of non-GAAP measures to GAAP measures provided in the Exhibits.
Investor Verification Checklist
- Verify the specific revenue and net loss figures for the quarter and six months ended June 30, 2022, in Exhibit 99.1 (Press Release).
- Review the reconciliation table in Exhibit 99.2 (Presentation) to understand the magnitude of adjustments made to derive non-GAAP operating loss.
- Confirm the Company's cash position and liquidity runway as detailed in the referenced financial statements.
- Assess the impact of excluded items (e.g., stock-based compensation, amortization) on the reported GAAP losses.